Abstract
Tumoral necrosis factor alpha blockers are very efficient in the treatment of many inflammatory systemic diseases, including rheumatoid arthritis and psoriasis. However, a paradoxical arouse of psoriasiform lesions may occur in a few patients taking anti-TNFα. The etiology of this rare side effect is still a mystery, and its treatment may be difficult. The authors report the resolution of adalimumab-induced psoriasis in a woman with rheumatoid arthritis after the use of high vitamin D(3) doses for the treatment of vitamin D deficiency. This is the first report of resolution of anti-TNFα-induced psoriasiform lesions by high doses of vitamin D(3) in a patient with rheumatoid arthritis and vitamin D deficiency. This case raises interesting questions on the role of vitamin D deficiency in the pathogenesis of this side effect and on the possible usefulness of high-dose vitamin D(3) in its treatment.
MeSH terms
-
Adalimumab
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use
-
Antirheumatic Agents / adverse effects*
-
Arthritis, Rheumatoid / complications
-
Arthritis, Rheumatoid / drug therapy*
-
Arthritis, Rheumatoid / immunology
-
Biomarkers / blood
-
Cholecalciferol / therapeutic use*
-
Drug Substitution
-
Female
-
Humans
-
Middle Aged
-
Psoriasis / chemically induced
-
Psoriasis / drug therapy*
-
Psoriasis / pathology
-
Risk Factors
-
Rituximab
-
Time Factors
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
-
Vitamin D / analogs & derivatives
-
Vitamin D / blood
-
Vitamin D Deficiency / blood
-
Vitamin D Deficiency / complications
-
Vitamin D Deficiency / diagnosis
-
Vitamin D Deficiency / drug therapy*
-
Vitamins / therapeutic use*
Substances
-
Antibodies, Monoclonal, Humanized
-
Antibodies, Monoclonal, Murine-Derived
-
Antirheumatic Agents
-
Biomarkers
-
Tumor Necrosis Factor-alpha
-
Vitamins
-
Vitamin D
-
Cholecalciferol
-
Rituximab
-
25-hydroxyvitamin D
-
Adalimumab